These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 30940711)

  • 41. Glucosylceramide Administration as a Vaccination Strategy in Mouse Models of Cryptococcosis.
    Mor V; Farnoud AM; Singh A; Rella A; Tanno H; Ishii K; Kawakami K; Sato T; Del Poeta M
    PLoS One; 2016; 11(4):e0153853. PubMed ID: 27082428
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Monoclonal antibodies recognizing the capsular polysaccharide of Cryptococcus neoformans].
    Rodríguez Sánchez H; Pupo Antúnez M; Ilnait MT; Otero A; Martínez Machín G
    Rev Cubana Med Trop; 2005; 57(2):162-4. PubMed ID: 17966590
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification and characterization of Cryptococcus neoformans protein fractions that induce protective immune responses.
    Chaturvedi AK; Weintraub ST; Lopez-Ribot JL; Wormley FL
    Proteomics; 2013 Dec; 13(23-24):3429-41. PubMed ID: 24170628
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of host immune responses to pulmonary cryptococcosis using a temperature-sensitive C. neoformans calcineurin A mutant strain.
    Wormley FL; Cox GM; Perfect JR
    Microb Pathog; 2005; 38(2-3):113-23. PubMed ID: 15748813
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice.
    Nussbaum G; Anandasabapathy S; Mukherjee J; Fan M; Casadevall A; Scharff MD
    Infect Immun; 1999 Sep; 67(9):4469-76. PubMed ID: 10456888
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The F-Box Protein Fbp1 Shapes the Immunogenic Potential of
    Masso-Silva J; Espinosa V; Liu TB; Wang Y; Xue C; Rivera A
    mBio; 2018 Jan; 9(1):. PubMed ID: 29317510
    [No Abstract]   [Full Text] [Related]  

  • 47. A Call to Arms: Quest for a Cryptococcal Vaccine.
    Caballero Van Dyke MC; Wormley FL
    Trends Microbiol; 2018 May; 26(5):436-446. PubMed ID: 29103990
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody.
    Zhang H; Zhong Z; Pirofski LA
    Infect Immun; 1997 Apr; 65(4):1158-64. PubMed ID: 9119446
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Killing of cryptococcus neoformans by Staphylococcus aureus: the role of cryptococcal capsular polysaccharide in the fungal-bacteria interaction.
    Saito F; Ikeda R
    Med Mycol; 2005 Nov; 43(7):603-12. PubMed ID: 16396245
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dectin-3 Recognizes Glucuronoxylomannan of
    Huang HR; Li F; Han H; Xu X; Li N; Wang S; Xu JF; Jia XM
    Front Immunol; 2018; 9():1781. PubMed ID: 30131805
    [No Abstract]   [Full Text] [Related]  

  • 51. UDP-Glucuronic Acid Transport Is Required for Virulence of
    Li LX; Rautengarten C; Heazlewood JL; Doering TL
    mBio; 2018 Jan; 9(1):. PubMed ID: 29382737
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Polysaccharide diversity in VNI isolates of Cryptococcus neoformans from Roraima, Northern Brazil.
    Dal Pupo HD; Sena BAG; Reis FCG; Machado L; Fortes ST; de Almeida Junior JN; Godinho RMC; Rodrigues ML
    Fungal Biol; 2019 Oct; 123(10):699-708. PubMed ID: 31542188
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies.
    Nakouzi A; Zhang T; Oscarson S; Casadevall A
    Vaccine; 2009 Jun; 27(27):3513-8. PubMed ID: 19464529
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cryptococcus inositol utilization modulates the host protective immune response during brain infection.
    Liu TB; Subbian S; Pan W; Eugenin E; Xie J; Xue C
    Cell Commun Signal; 2014 Sep; 12():51. PubMed ID: 25201772
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of antibody to capsular polysaccharide on eosinophilic pneumonia in murine infection with Cryptococcus neoformans.
    Feldmesser M; Kress Y; Casadevall A
    J Infect Dis; 1998 Jun; 177(6):1639-46. PubMed ID: 9607844
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide.
    Lendvai N; Casadevall A; Liang Z; Goldman DL; Mukherjee J; Zuckier L
    J Infect Dis; 1998 Jun; 177(6):1647-59. PubMed ID: 9607845
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cryptococcus neoformans glucuronoxylomannan fractions of different molecular masses are functionally distinct.
    Albuquerque PC; Fonseca FL; Dutra FF; Bozza MT; Frases S; Casadevall A; Rodrigues ML
    Future Microbiol; 2014; 9(2):147-61. PubMed ID: 24571070
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures.
    Oscarson S; Alpe M; Svahnberg P; Nakouzi A; Casadevall A
    Vaccine; 2005 Jun; 23(30):3961-72. PubMed ID: 15917118
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regulation of cytokine expression in mice immunized with cryptococcal polysaccharide, a glucuronoxylomannan (GXM), associated with peritoneal antigen-presenting cells (APC): requirements for GXM, APC activation, and interleukin-12.
    Blackstock R; McElwee N; Neller E; Shaddix-White J
    Infect Immun; 2000 Sep; 68(9):5146-53. PubMed ID: 10948138
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cryptococcus neoformans: paradigm for the role of antibody immunity against fungi?
    Pirofski LA; Casadevall A
    Zentralbl Bakteriol; 1996 Aug; 284(4):475-95. PubMed ID: 8899968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.